EP1579862A1 — Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
Assigned to Boehringer Ingelheim Vetmedica GmbH · Expires 2005-09-28 · 21y expired
What this patent protects
The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca 2+ -sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failu…
USPTO Abstract
The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca 2+ -sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.